The PE Ratio as of November 2024 (TTM) for Deciphera Pharmaceuticals, Inc. (DCPH) is -11.58

According to Deciphera Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -11.58. This represents a change of 73.40% compared to the average of -6.68 of the last 4 quarters.

Deciphera Pharmaceuticals, Inc. (DCPH) Historical PE Ratio (quarterly & annually)

How has DCPH PE Ratio performed in the past?

The mean historical PE Ratio of Deciphera Pharmaceuticals, Inc. over the last ten years is -9.95. The current -11.58 PE Ratio has changed 11.53% with respect to the historical average. Over the past ten years (40 quarters), DCPH's PE Ratio was at its highest in in the September 2017 quarter at -0.81. The PE Ratio was at its lowest in in the June 2018 quarter at -15.22.

Deciphera Pharmaceuticals, Inc. (DCPH) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Deciphera Pharmaceuticals, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Deciphera Pharmaceuticals, Inc. (DCPH) Average PE Ratio

How has DCPH PE Ratio performed in the past?

The current PE Ratio of Deciphera Pharmaceuticals, Inc. (DCPH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Deciphera Pharmaceuticals, Inc. (DCPH) PE Ratio vs. Peers

How is DCPH’s PE Ratio compared to its peers?

Deciphera Pharmaceuticals, Inc.’s PE Ratio is less than Eagle Pharmaceuticals, Inc. (0.34), greater than ANI Pharmaceuticals, Inc. (-155.73), less than Phibro Animal Health Corporation (55.24), less than Prestige Consumer Healthcare Inc. (20.46), less than Evotec SE (-4.46), less than Supernus Pharmaceuticals, Inc. (33.45), less than Collegium Pharmaceutical, Inc. (10.91), less than Neurocrine Biosciences, Inc. (32.92), less than Ironwood Pharmaceuticals, Inc. (21.99), less than Alkermes plc (14.10), greater than Avadel Pharmaceuticals plc (-15.47), less than Amphastar Pharmaceuticals, Inc. (14.01), less than Procaps Group S.A. (2.68), less than Silver Spike Investment Corp. (13.39),

Build a custom stock screener for Deciphera Pharmaceuticals, Inc. (DCPH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Deciphera Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Deciphera Pharmaceuticals, Inc. (DCPH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Deciphera Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.